Please use this identifier to cite or link to this item: https://doi.org/10.1517/17425255.2012.694867
Title: An update on chemotherapy and tumor gene expression profiles in breast cancer
Authors: Tan, S.-H.
Lee, S.-C. 
Keywords: Breast cancer
Chemotherapy
Gene expression
Neoadjuvant
Issue Date: Sep-2012
Citation: Tan, S.-H., Lee, S.-C. (2012-09). An update on chemotherapy and tumor gene expression profiles in breast cancer. Expert Opinion on Drug Metabolism and Toxicology 8 (9) : 1083-1113. ScholarBank@NUS Repository. https://doi.org/10.1517/17425255.2012.694867
Abstract: Introduction: Various trials have attempted to develop gene expression profiles (GEPs) that may provide a better predictor of clinical outcome over traditional clinicopathological criteria. Areas covered: The review focuses on two main areas: trials examining chemotherapy-induced GEP changes pre- and post-treatment, and studies correlating baseline signatures with chemosensitivity. In the first part of the article, the authors specifically cover areas pertaining to general/drug-specific tumor GEP changes and GEP changes between responders versus non-responders in specific molecular subclasses. The authors also discuss non-tumor-specific signatures, and provide a comparison of different biopsy methods. The authors also discuss the challenges that must be overcome in this area, looking at the clinical application of gene expression profiling and some of the multigene assays which have gained clinical utility. Expert opinion: Current studies are challenged by a number of issues including: small sample sizes, retrospective analyses, varying chemotherapy regimens and response end points, the need for fresh frozen samples, distinct gene signatures in multiple platforms with minimal overlap and inherent microarray technological complexities. To date, no pharmacogenomic drug-specific predictor has been implemented clinically. Future studies should focus on distinct molecular subgroups by pooling resources and validation in well-powered randomized trials. Incorporating GEPs with newer biotechnological modalities may provide a more robust predictive model. © 2012 Informa UK, Ltd.
Source Title: Expert Opinion on Drug Metabolism and Toxicology
URI: http://scholarbank.nus.edu.sg/handle/10635/117343
ISSN: 17425255
DOI: 10.1517/17425255.2012.694867
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

2
checked on Jun 15, 2018

WEB OF SCIENCETM
Citations

4
checked on May 22, 2018

Page view(s)

40
checked on May 11, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.